-
Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards
Wednesday, November 20, 2024 - 4:15pm | 338Psyence Biomedical Ltd. (NASDAQ:PBM) has successfully obtained an extension from the Nasdaq Hearings Panel, giving the company until December 31, 2024, to meet the exchange's continued listing requirements. The decision, reached after a hearing on October 31, allows the company to remain listed...
-
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Monday, September 16, 2024 - 1:42pm | 264Psyence Biomedical Ltd. (NASDAQ:PBM), a biotechnology company focused on creating natural psychedelic-based solutions to address mental health challenges, has issued an update to shareholders, highlighting significant recent developments and upcoming milestones. The company has initiated a Phase...
-
Magic Mushrooms Vs. Psychotherapy For Incurable Cancer Diagnosis Moves Forward In UK Clinical Trials
Monday, September 19, 2022 - 12:59pm | 562UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Psyence Group Inc. (OTCQB: PSYGF)’s application to assess the efficacy and safety of psilocybin-assisted psychotherapy compared to psychotherapy alone for treating adjustment disorder following an incurable...